OVID

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced several strategic appointments strengthening its executive leadership team to support the Company's next phase of development.

Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated safety profile; Phase 2 trials begin Q2 2026. Secondary asset OV4071, now in Phase 1, pivots toward the lucrative schizophrenia/psychosis market, offering pipeline diversification.

Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and pharmacologic profile versus first-generation Sabril, targeting rare epilepsies. Phase 2 expansion includes POC studies in photosensitive seizures, treatment-resistant FOS, TSC-associated seizures, and infantile spasms, with key catalysts in 2026-2027.

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences:

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026.

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studies Announced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanism Strengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participation from leading healthcare investors Received $53.9 million in gross proceeds upon full exercise of Series A warrants in connection with October 2025 PIPE financing Cash, cash equivalents and marketable securities were $165.6 million as of March 31, 2026, which does not include $27.3 million in proceeds received in April 2026 from exercise of Series A warrants NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the first quarter ended March 31, 2026. “Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions,” stated Meg Alexander, President and Chief Executive Officer.